ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced that updated clinical data from a fully enrolled Phase 1 trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) being held in Orlando, Florida, December 4-7, 2010. These Phase 1 findings in patients with resistant and refractory chronic myeloid leukemia (CML) will be featured in an oral presentation and will also be highlighted in a webcast investor meeting being held at ASH.
Presentation of Data:
A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings
Presenter: Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia at the University of Texas MD Anderson Cancer Center
Oral Session: Chronic Myeloid Leukemia - Therapy: Optimizing Treatment Outcome
Date and Time: Monday, December 6, 2010, 8:15 a.m. ET
Location: Orange County Convention Center, Valencia A
Source: ARIAD